Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.

Benedikt SchaeferMoritz TobiaschAndré ViveirosHerbert TilgNicholas A KennedyMyles WolfHeinz Zoller

Published in: British journal of clinical pharmacology (2020)

FCM is associated with a high risk of hypophosphataemia, which does not resolve for at least 3 months in a large proportion of affected patients. More severe iron deficiency and normal kidney function are risk factors for hypophosphataemia.

Keyphrases

iron deficiency
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes